Drug K of "medical fast reading society" has been approved as the first PD-1 therapy for NMIBC

The drugstore can only increase the price by 15% and sell drugs at a maximum of 200 yuan; two pharmaceutical companies apply for cancellation of the drug production license; drug K has been approved as the first PD-1 treatment for NMIBC with new indications; Cefradine capsule of Lufan medicine has passed the consistency evaluation On August 8, Zhejiang provincial medical insurance bureau released the reform plan (Draft for comments) to improve the function of centralized drug procurement and promote the full coverage of medical insurance drug payment standards The plan puts forward specific measures for centralized purchase of drugs and payment standards for medical insurance drugs Fixed point retail pharmacies can only increase the price of drugs on the centralized purchase platform by 15%, and the maximum price can only be increased by 200 yuan (Zhejiang Medical Insurance Bureau) Recently, Shanghai Sunshine pharmaceutical purchasing network released the document "notice on online purchasing of Aminophylline Injection and other clinical drugs in short supply" In order to meet the needs of clinical drug use, through research and decision, it is agreed that Aminophylline Injection and other drugs produced by Shiyao Yinhu Pharmaceutical Co., Ltd shall be purchased online According to the requirements of "overall online open price negotiation", the purchase price of drugs in clinical shortage shall be negotiated independently by designated medical institutions and drug manufacturers (Shanghai sunshine medicine purchasing network) On August 8, Guangdong food and Drug Administration issued the notice of cancellation of drug production license (No 04, 2019) According to the relevant provisions of the drug administration law of the people's Republic of China, the regulations for the implementation of the drug administration law of the people's Republic of China and the measures for the supervision and administration of drug production, the drug production license of Shaoguan resident Pharmaceutical Co., Ltd and Guangdong Guoyitang Pharmaceutical Co., Ltd shall be cancelled and withdrawn according to law (Sina Medical News) Recently, minimally invasive medical announced that it is considering to split the shares of the non wholly owned subsidiary microport cardioflow and list them separately (notice of minimally invasive medicine) On September 9, virtual precision announced the completion of a $20 million B + round of financing to promote the research and development of its first micro surgical robot Mira At the same time, it also announced that it has submitted Mira's application for clinical trial exemption (IDE) of medical devices to the US FDA (chuangjianhui) Northsea therapeutics, a Dutch biomedical company, announced the completion of a round B financing of US $40 million, which will be mainly used in iconA, a phase 2B clinical study on the treatment of nonalcoholic steatohepatitis (NASH) patients with its first of its kind, oral structured fatty acid (Sefa) drug icosabutate (chuangjianhui) On January 8, local time, FDA of the United States announced the approval of keysruda (pembrolizumab), a PD-1 inhibitor of methadone, as a single drug therapy for the treatment of specific high-risk non muscle invasive bladder cancer (NMIBC) patients, specifically: not eligible for bladder resection or has chosen not to undergo bladder resection of BCG vaccine non response, high-risk, with in situ cancer (CIS), with or without papillary lesions of nm IBC patients (Sina Medical News) Astaire recently announced that the U.S FDA has approved the application of mycamine (micafungin injection) as a new drug supplement for infants under 4 months to treat candidemia, acute disseminated candidiasis, candidal peritonitis and abscesses without meningitis and / or eye transmission (Sina Medical News) Today, blue medicine announced that its highly selective RET inhibitor, pralsettinib (blu-667), has achieved positive top line results in the 1 / 2 phase of clinical research arrow for patients with RET fusion positive non-small cell lung cancer Blueprint medicines has begun to submit a rolling new drug application for this indication to the US FDA, which is expected to be completed in the first quarter of this year (yaomingkant) The clinical application of tqj230 injection submitted by Novartis in China has been accepted by CDE, according to the official CDE website on August 8 The pioneering therapy of this specific anti sense drug targeting at the rise of lipoproteins (a) has started the listing process in the Chinese market ( On September 9, Lu Kang medicine announced that the company had recently received the approval document for supplementary drug application (approval No.: 2019b04626) issued by the State Food and Drug Administration on Cefradine capsule (0.25g), which passed the consistency evaluation of quality and efficacy of generic drugs (Sina Medical News) On January 9, Zhongsheng pharmaceutical announced that South China pharmaceutical, a wholly-owned subsidiary of the company, had recently received the approval document for supplementary drug application approved and issued by the State Food and Drug Administration with the approval number of 2019b04697 According to the website of the drug evaluation center of the State Food and drug administration, no other enterprises in China have applied for the conformity assessment of the quality and efficacy of generic drugs of Dextromethorphan Hydrobromide South China pharmaceutical industry is the only enterprise in China that has applied for the application of Dextromethorphan Hydrobromide tablets according to the conformity assessment policy of the quality and efficacy of generic drugs (Sina Medical News) Today, versastem oncology announced that it has reached a global exclusive license agreement with Chugai Pharmaceutical Co., Ltd of Japan Versastem has obtained the global development and promotion rights of CHF / MEK inhibitor ch5126766 (cki27) developed by Chugai Currently, ch5126766 is being developed to treat solid tumor patients with KRAS mutation (yaomingkant)